Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 1
2024 pubmed 1 citations

Association between dysbiotic perio-pathogens and inflammatory initiators and mediators in COVID-19 patients with diabetes.

Bachtiar. Endang W EW; Bachtiar. Boy M BM; Kusumaningrum. Ardiana A; Sunarto. Hari H; Soeroso. Yuniarti Y; Sulijaya. Benso B; Theodorea. Citra Fragrantia CF; Pratomo. Irandi Putra IP; Efendi. Defi D; Apriyanti. Efa E; Said. Shahida Mohd SM

Key Findings

  • ACE2 was present in all gum‑disease patients, but only those with diabetes showed a strong link to inflammation markers
  • IL‑6 and complement C3 together could predict the level of periodontal inflammation in diabetic COVID‑19 patients
  • LL‑37 levels were measured but did not correlate strongly with disease severity

Practical Outcomes

  • For biohackers, the main takeaway is that maintaining good oral health may be especially important for people with diabetes during COVID‑19, but the study doesn’t provide any new peptide‑based treatments or dosage advice.

Summary

The study looked at people with gum disease who also had COVID‑19, comparing those with and without diabetes. It found that a virus‑entry protein (ACE2) and inflammation signals were linked mainly in the diabetic group, and that a combo of two inflammation markers (IL‑6 and complement C3) could hint at how bad the gum inflammation is. The peptide LL‑37 was measured but didn’t show a clear role.

Abstract

It has been suggested that a corona virus infection is linked to chronic periodontitis (COVID-19). Our objectives were to look at the expression of angiotensin-converting enzyme-2 (ACE2) in periodontal compartments containing periodontal infections to determine if ACE2 is directly or indirectly responsible for the inflammation in periodontal tissues getting worse. In this study, six non-COVID-19 periodontitis patients without diabetes served as controls, and 23 hospitalized periodontitis patients were admitted with PCR-confirmed COVID-19 with diabetes mellitus (Group 1/G1, n&#xa0;=&#xa0;10), and without diabetes (Group 2/G2, n&#xa0;=&#xa0;13). We evaluated the mRNA expression of ACE2, IL-6, IL-8, complement C3, and LL-37, as well as the relative proportion of <i>Porphyromonas gingivalis</i>, <i>Fusobacterium nucleatum</i>, and <i>Veillonella parvula</i> to represent the dysbiosis condition in periodontal microenvironment using subgingival plaque and gingival crevicular fluids (GCF) samples and quantitative real time PCR (qPCR). Every analysis was done to ascertain how they related to one another. The area under the curve (AUC) and receiver operating characteristic (ROC) curve were used to determine the sensitivity and specificity of inflammatory indicators. All the grouped patients had ACE2 detected, according to our findings, but only the G1 patients had a positive correlation (p&#xa0;&lt;&#xa0;0.05) between ACE2 expression and the inflammatory markers. The combination of IL-6 and C3 mRNAs was found to be 0.78 and 0.55 for the G1 group and the G2 group, respectively, based on the ROC and AUC values. According to our research, the relationship between complement C3 and IL-6 may be able to predict the degree of periodontal inflammation in COVID-19 patients who also have diabetes.

Study Information

Provider

pubmed

Year

2024

Date

2024-01-06T00:00:00.000Z

DOI

10.1016/j.heliyon.2024.e24089

Citations

1

References

35